1887
Preview this article:
Zoom in
Zoomout

In vitro activity of antimicrobial agents against multidrug- and extensively drug-resistant Acinetobacter baumannii, Page 1 of 1

| /docserver/preview/fulltext/jmm/66/1/98_jmm000422-1.gif

There is no abstract available for this article.
Use the preview function to the left.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000422
2017-02-20
2019-10-21
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/1/98.html?itemId=/content/journal/jmm/10.1099/jmm.0.000422&mimeType=html&fmt=ahah

References

  1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538–582 [CrossRef][PubMed]
    [Google Scholar]
  2. Marra AR, Camargo LF, Pignatari AC, Sukiennik T, Behar PR et al. Nosocomial bloodstream infections in Brazilian hospitals: analysis of 2,563 cases from a prospective nationwide surveillance study. J Clin Microbiol 2011;49:1866–1871 [CrossRef][PubMed]
    [Google Scholar]
  3. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008;8:751–762 [CrossRef][PubMed]
    [Google Scholar]
  4. Evans BA, Amyes SG. OXA β-lactamases. Clin Microbiol Rev 2014;27:241–263 [CrossRef][PubMed]
    [Google Scholar]
  5. Rossi F. The challenges of antimicrobial resistance in Brazil. Clin Infect Dis 2011;52:1138–1143 [CrossRef][PubMed]
    [Google Scholar]
  6. Grosso F, Carvalho KR, Quinteira S, Ramos A, Carvalho-Assef AP et al. OXA-23-producing Acinetobacter baumannii: a new hotspot of diversity in Rio de Janeiro?. J Antimicrob Chemother 2011;66:62–65 [CrossRef][PubMed]
    [Google Scholar]
  7. Chagas TP, Carvalho KR, de Oliveira Santos IC, Carvalho-Assef AP, Asensi MD. Characterization of carbapenem-resistant Acinetobacter baumannii in Brazil (2008-2011): countrywide spread of OXA-23-producing clones (CC15 and CC79). Diagn Microbiol Infect Dis 2014;79:468–472 [CrossRef][PubMed]
    [Google Scholar]
  8. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008;46:1121–1122 [CrossRef][PubMed]
    [Google Scholar]
  9. Chang HC, Wei YF, Dijkshoorn L, Vaneechoutte M, Tang CT et al. Species-level identification of isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex by sequence analysis of the 16S-23S rRNA gene spacer region. J Clin Microbiol 2005;43:1632–1639 [CrossRef][PubMed]
    [Google Scholar]
  10. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing M100-S25 Wayne, PA: CLSI; 2015
    [Google Scholar]
  11. Clinical and Laboratory Standards Institute Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically M07-A9 Wayne, PA: CLSI; 2012
    [Google Scholar]
  12. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–281 [CrossRef][PubMed]
    [Google Scholar]
  13. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 2006;27:351–353 [CrossRef][PubMed]
    [Google Scholar]
  14. Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H. OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 2009;53:5035–5038 [CrossRef][PubMed]
    [Google Scholar]
  15. Seifert H, Dolzani L, Bressan R, van der Reijden T, van Strijen B et al. Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter baumannii. J Clin Microbiol 2005;43:4328–4335 [CrossRef][PubMed]
    [Google Scholar]
  16. Camargo CH, Tiba MR, Saes MR, Vasconcellos FM, Santos LF et al. Population structure analysis of carbapenem-resistant Acinetobacter baumannii clinical isolates from Brazil reveals predominance of clonal complexes 1, 15, and 79. Antimicrob Agents Chemother 2016;60:2545–2547 [CrossRef][PubMed]
    [Google Scholar]
  17. US Centers for Disease Control and Prevention Antibiotic resistance threats in the United States 2013. www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf
  18. Castanheira M, Mendes RE, Jones RN. Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. Clin Infect Dis 2014;59:S367–S373 [CrossRef][PubMed]
    [Google Scholar]
  19. Bishburg E, Bishburg K. Minocycline – an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob Agents 2009;34:395–401 [CrossRef][PubMed]
    [Google Scholar]
  20. Falagas ME, Rafailidis PI, Matthaiou DK. Resistance to polymyxins: mechanisms, frequency and treatment options. Drug Resist Updat 2010;13:132–138 [CrossRef][PubMed]
    [Google Scholar]
  21. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006;10:R27 [CrossRef][PubMed]
    [Google Scholar]
  22. Cardoso JP, Cayô R, Girardello R, Gales AC. Diversity of mechanisms conferring resistance to β-lactams among OXA-23-producing Acinetobacter baumannii clones. Diagn Microbiol Infect Dis 2016;85:90–97 [CrossRef][PubMed]
    [Google Scholar]
  23. Ni W, Han Y, Zhao J, Wei C, Cui J et al. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int J Antimicrob Agents 2016;47:107–116 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000422
Loading
/content/journal/jmm/10.1099/jmm.0.000422
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error